Trial Profile
A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs CJRB 102 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors 4D Pharma PLC
- 30 May 2023 Status changed from active, no longer recruiting to discontinued.
- 05 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 31 Mar 2022 According to a 4D pharma media release, the company will provide update on next steps in Phase I/II study of MRx0518 and Keytruda in the Renal Cell Carcinoma (RCC) group in 2022.